Cargando…
Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor
PURPOSE: To assess the prognostic and predictive value of circulating ESR1 mutation and its kinetics before and after progression on aromatase inhibitor (AI) treatment. PATIENTS AND METHODS: ESR1 circulating D538G and Y537S/N/C mutations were retrospectively analyzed by digital droplet PCR after fir...
Autores principales: | Clatot, Florian, Perdrix, Anne, Augusto, Laetitia, Beaussire, Ludivine, Delacour, Julien, Calbrix, Céline, Sefrioui, David, Viailly, Pierre-Julien, Bubenheim, Michael, Moldovan, Cristian, Alexandru, Cristina, Tennevet, Isabelle, Rigal, Olivier, Guillemet, Cécile, Leheurteur, Marianne, Gouérant, Sophie, Petrau, Camille, Théry, Jean-Christophe, Picquenot, Jean-Michel, Veyret, Corinne, Frébourg, Thierry, Jardin, Fabrice, Sarafan-Vasseur, Nasrin, Di Fiore, Frédéric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342678/ https://www.ncbi.nlm.nih.gov/pubmed/27801670 http://dx.doi.org/10.18632/oncotarget.12950 |
Ejemplares similares
-
Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients
por: Allouchery, Violette, et al.
Publicado: (2018) -
Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer
por: Clatot, Florian, et al.
Publicado: (2020) -
Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma
por: Drouyer, Aurélien, et al.
Publicado: (2023) -
Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients
por: Allouchery, Violette, et al.
Publicado: (2021) -
Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours
por: Sefrioui, David, et al.
Publicado: (2017)